Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.1t | $1174.75 | +0.6% | 2.2M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $253.31 | +1.1% | 7.5M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $444.6b | $254.38 | +0.0% | 5.2M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $317.4b | $127.58 | +0.0% | 10.7M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $294.1b | $168.30 | +0.2% | 1.8M |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $195.4b | $364.85 | -1.5% | 2.1M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $186.3b | $530.38 | -2.0% | 1.1M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $156.9b | $134.40 | -1.5% | 5.1M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $137.2b | $25.07 | -0.3% | 33.4M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $126.1b | $486.51 | -0.1% | 776.5K |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $117.7b | $60.89 | +0.5% | 9.8M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $65.4b | $676.50 | -0.3% | 479.2K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.2b | $268.18 | -5.6% | 1.1M |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $37.5b | $132.06 | -3.4% | 1.9M |
 WAT | Waters Corp | Clinical-Stage Platforms | $36.8b | $368.86 | -2.4% | 470.7K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $32.2b | $204.77 | -2.0% | 1.1M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $31.9b | $205.05 | -1.4% | 892.7K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $27.8b | $61.87 | -2.1% | 3.9M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $25.5b | $34.52 | +1.7% | 2.5M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $25.4b | $368.00 | -1.2% | 531.2K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $24.9b | $58.31 | -0.6% | 2.2M |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $23.1b | $109.04 | +0.8% | 1.7M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.0b | $535.63 | +1.3% | 310.2K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $22.6b | $117.64 | +0.5% | 1.6M |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $17.5b | $261.11 | +0.6% | 596.3K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $16.9b | $171.60 | -0.5% | 645.4K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.1b | $248.12 | +2.2% | 390.2K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $15.1b | $534.30 | -0.1% | 195.8K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $14.6b | $79.99 | +1.4% | 1.1M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $13.3b | $170.09 | -0.0% | 520.5K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $13.1b | $54.71 | -0.5% | 2.2M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $12.6b | $229.90 | -3.0% | 665.5K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $12.4b | $110.13 | -1.4% | 1.0M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $12.4b | $545.82 | +1.4% | 283.4K |
 CYTK | Cytokinetics Inc. | Neuroscience & CNSRare Disease Therapeutics | $11.6b | $80.80 | -0.3% | 1.4M |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $11.5b | $74.72 | +4.2% | 2.1M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $11.3b | $13.92 | +0.4% | 2.5M |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $58.50 | -0.7% | 1.0M |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.0b | $71.70 | +0.5% | 2.5M |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $11.0b | $354.52 | +3.8% | 263.6K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $10.9b | $224.34 | -2.1% | 572.0K |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.0b | $133.78 | -0.1% | 1.7M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $9.4b | $115.83 | +1.5% | 623.8K |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $9.3b | $90.55 | +0.8% | 855.8K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.3b | $314.74 | +1.9% | 242.8K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $9.3b | $77.80 | +0.3% | 1.1M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $9.2b | $7.69 | +2.8% | 8.3M |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.2b | $58.21 | -1.7% | 1.3M |
 ALKS | Alkermes Inc. plc | Neuroscience & CNS | $8.7b | $52.70 | +1.5% | 962.2K |
 TGTX | TG Therapeutics, Inc. | Immunology & AutoimmuneNeuroscience & CNS | $8.4b | $55.43 | -0.1% | 1.3M |